Abstract: A thermally conductive microplate made of thermoplastic material, comprising a microplate body (150) having at least 96 wells (151) arranged in the microplate body (150), the microplate body (150) having a flat microplate bottom (154), and each well (151) having at least one well wall (152) and a planar well bottom (153) which is aligned with a well bottom plane (200) shared by all well bottoms (153) and has a bottom thickness of at most 1000 ?m. Also disclosed is a method for producing the thermally conductive microplates. The microplate body (150) is preferably arranged in a frame carrier (300), in particular is welded, adhesively bonded or riveted thereto. Having high thermal conductivity, upright-format thermally conductive microplates are optimised for automated processing in analysis and synthesis methods that are temperature sensitive and based on temperature change.

Abstract: The invention relates to a system comprising at least one disposable comprising one or more wells in a body, wherein the wells are capable of acting as vessel for one or more chemical, biochemical or molecular biological reactions requiring one or more prescribed reaction temperatures according to a prescribed protocol, said body comprising a flat bottom side building a first heating surface capable of homogeneously conducting heat into the wells and a flat upper side comprising well openings sealed by means of a transparent sealing foil building a second heating surface capable of homogeneously conducting heat in the wells, said body being arranged in a rigid frame support; one or more separate tempering units TUx, each tempering unit TUx comprising at least one first temperature-controlled plates with a planar seat to conform to the flat bottom side of the disposable; transport means comprising a carrier in which the disposable is placed and a moving mechanism for moving the disposable into and/or out of th

Abstract: A switchable hydraulic bearing for mounting of a motor-vehicle assembly comprises a support bearing and a mount connected by a support spring, and a working chamber and an equalization chamber fillable with damping liquid that are spatially separated by a separating wall and connected by a damping channel in the separating wall. The separating wall may comprise a nozzle cage with two adjacent nozzle discs provided with an axial spacing. A diaphragm of rubber-elastic material may be provided in a gap between the nozzle discs. The diaphragm may be switchable by a switching device comprising an elastic lever disc axially adjacent to the second nozzle disc. An electromagnet may connect to the lever disc and can adjust the lever disc between a first position, permitting axial play of the diaphragm in the gap, and a second position, acting on the second nozzle disc and clamping the diaphragm between nozzle discs.

Abstract: A lysis buffer comprising one non-ionic surfactant is provided which can be used as a one-step reagent of the preparation, storage, amplification, and/or detection of nucleic acids. Various embodiments of the lysis buffer of the invention comprise other substances that are compatible or useful in lysing cells, storing nucleic acids, amplifying nucleic acids, purifying nucleic acids, detecting nucleic acids, and/or other procedures for analysis of nucleic acids. Methods and kits based on the lysis buffer are also provided, including those for rapid lysis of cells and direct use of the resulting cell lysates in RT-PCR.

Abstract: A hydraulically damping mount for mounting a motor vehicle unit on a motor vehicle body includes a support and a support mount which are interconnected by a support spring made of an elastomeric material. In embodiments, a support spring limits a working chamber which is separated from a compensating chamber by a separating device, wherein the working chamber and the compensating chamber may be filled with a fluid and may be connected to one another via a damping channel included in the separating device, wherein the separating device may include two nozzle discs between which a first membrane and a second membrane are arranged, and wherein one of the membranes has at least one through-hole.

Abstract: A hydraulically damping mount for mounting a motor vehicle unit on a motor vehicle body includes a support and a support mount which are interconnected by a support spring made of an elastomeric material. In embodiments, a support spring limits a working chamber which is separated from a compensating chamber by a separating device, wherein the working chamber and the compensating chamber may be filled with a fluid and may be connected to one another via a damping channel included in the separating device, wherein the separating device may include two nozzle discs between which a first membrane and a second membrane are arranged, and wherein one of the membranes has at least one through-hole.

Abstract: The present invention relates to substituted N-(phenyl-heteroaryl)-3-acetylamino-benzamides and N-[3-(acetylamino)phenyl]-phenyl-heteroaryl-carboxamides of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease such as cancer, wherein i.a.: LA represents an optionally substituted methylene or ethylene group; LB represents —N(H)—C(?O)— or —C(?O)—N(H)—; R1 represents an optionally substituted 5- to 8-membered heterocycloalkyl, 4- to 10-membered heterocycloalkenyl, aryl, heteroaryl or —N(R7)(Ci-C6-alkyl) group; R2 represents an optionally substituted 5- or 6-membered heteroaryl group; R3 represents an optionally substituted phenyl group.

Abstract: The present invention relates to the use of cathepsin K and/or cathepsin S inhibitors in a method for the treatment and/or prophylaxis of pulmonary hypertension and/or heart failure.

Abstract: The present invention relates to inhibitors of the Wnt signalling pathways of general formula (I) wherein LA represents *CH2** or *?**; wherein indicates the point of attachment to the carbonyl group, and ** indicates the point of attachment to R1; LB represents *N(H)—C(?O)** or *C(?O)—N(H)**; wherein * indicates the point of attachment to R2, and ** indicates the point of attachment to the phenyl group; R1 represents a group selected from: (AA); wherein * indicates the point of attachment to LA, R2 represents: (BB) wherein * indicates the point of attachment to R3, and ** indicates the point of attachment to LB R3 represents a group selected from: (CC); wherein * indicates the point of attachment to R2; R4 and R5 represent a hydrogen atom; and R6 represents a halogen atom or group selected from: —CH3, —O—CH3, —O—CHF2, —O—CF3, and —O-cyclopropyl; to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing

Abstract: The present invention relates to inhibitors of the Wnt signalling pathways of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative disorder, as a sole agent or in combination with other active ingredients.

Abstract: The present invention relates to amido-substituted azole compounds of general formula (I), in which X1, X2, R1, R2, R4, R5, R7 and R8 are as defined in the claims which are inhibitors of TNKS1 and/or TNKS2, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.

Abstract: The present invention relates to inhibitors of the Wnt signalling pathways of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative disorder, as a sole agent or in combination with other active ingredients, in which: R1 represents a group selected from: C1-C3-alkoxy-C2-C3-alkyl-, (A), (B), (C), (D), (E), (F), (G) or (H); wherein * indicates the point of attachment to the rest of the molecule; R2 represents a group selected from: (I), (J) or (K); wherein * indicates the point of attachment to the rest of the molecule.

Abstract: The invention provides human AdipoR2 which is associated with the cardiovascular diseases, dermatological diseases, gastroenterological diseases, cancer, hematological diseases, respiratory diseases, inflammation, neurological diseases, urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, dermatological diseases, gastroenterological diseases, cancer, hematological diseases, respiratory diseases, inflammation, neurological diseases, urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of AdipoR2 as well as pharmaceutical compositions comprising such compounds.

Abstract: The invention relates to the nucleotide and amino acid sequences, and to the activity and use, of the luciferases LuAL, Lu164, Lu16, Lu39, Lu45, Lu52 and Lu22.

Abstract: The present invention relates to inhibitors of the Wnt signalling pathways of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative disorder, as a sole agent or in combination with other active ingredients.

Abstract: The present invention relates to inhibitors of the Wnt signalling pathways of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative disorder, as a sole agent or in combination with other active ingredients.

Abstract: The present invention relates to substituted N-(phenyl-heteroaryl)-3-acetylamino-benzamides and N-[3-(acetylamino)phenyl]-phenyl-heteroaryl-carboxamides of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease such as cancer, wherein i.a.: LA represents an optionally substituted methylene or ethylene group; LB represents —N(H)—C(?0)- or —C(?0)—N(H)—; R1 represents an optionally substituted 5- to 8-membered heterocycloalkyl, 4- to 10-membered heterocycloalkenyl, aryl, heteroaryl or —N(R7)(Ci-C6-alkyl) group; R2 represents an optionally substituted 5- or 6-membered heteroaryl group; R3 represents an optionally substituted phenyl group.

Abstract: The present invention is in the field of molecular biology, more particularly, the present invention relates to drug screening, assay development and identification and use of modulators for G-protein coupled receptor/ligand pair MRGX2/CXCL14 within drug discovery.

Abstract: The present invention relates to substituted N-biphenyl-3-acetylamino-benzamides and N-[3-(acetylamino)phenyl]-biphenyl-carboxamides of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disorder, as a sole agent or in combination with other active ingredients.

Abstract: The invention relates to the nucleotide and amino acid sequences, and to the activity and use, of the luciferases LuAL, Lu164, Lu16, Lu39, Lu45, Lu52 and Lu22.